Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers

Stroke Clinical Trial

Official title: An Open-label, One-sequence, Three-period, Multiple-dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability Between NDC-002A/NDC-002B and NDC-002C in Healthy Volunteers

Status Completed

Clinical Trial Summary

An Open-label, One-sequence, Three-period, Multiple-dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability between NDC-002A/NDC-002B and NDC-002C in Healthy Volunteers

Clinical Trial Description

This is an Open-label, One-sequence, Three-period, Multiple-dose Study and the goal of this clinical trial is to evaluate in health Volunteers. The main question[s] it aims to answer are: - Drug-drug Interactions - Safety - Tolerability The study consisted of Three-period: Period 1 which repeated administration of NDC-002C for 7 days and Period 2 which repeated administration of NDC-002A for 7 days, followed by administration of NDC-002B for 8 days and Period 3 which repeated concomitant administration of NDC-002B and NDC-002C for 7 days. ;

Related Conditions & MeSH terms

• Stroke
• Stroke Sequelae

• NCT number: NCT06090474
• Study type: Interventional
• Source: Dr. Noah Biotech Inc.
• Status: Completed
• Phase: Phase 1
• Start date: January 12, 2023
• Completion date: March 15, 2023